Inovio Pharmaceuticals, Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing the pricing and terms of a public offering of common stock and pre-funded warrants expected to generate approximately $80.5 million in net proceeds.
Atea Pharmaceuticals, Inc. filed a Current Report on Form 8-K on November 9, 2026, disclosing that it entered into a Loan and Security Agreement with Hercules Capital, Inc. on November 6, 2026, providing for term loans of up to $200.0 million.
Netcapital Inc. filed a current report on November 9, 2026, disclosing that Nasdaq granted the company an exception period running through February 9, 2027, to file its overdue Annual Report and Quarterly Report after receiving delinquency notifications in August and September 2026.
Ocular Therapeutix, Inc. filed a current report on November 9, 2026, disclosing the election of Riad Sherif, M.D. to its Board of Directors effective November 6, 2026, and the forthcoming resignation of Seung Suh Hong, Ph.D., effective December 31, 2026.
The Goodyear Tire & Rubber Company filed a Form 8-K on November 9, 2026, disclosing that Roger J. Wood was appointed Interim Chief Executive Officer and President effective November 8, 2026, replacing Mark W. Stewart, whose separation was classified as a termination "other than …
Soluna Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing via Regulation FD that it will release its third quarter 2026 financial results on November 16, 2026, and host a conference call and webcast at 5:00 PM ET that day.
FACT II Acquisition Corp. filed a current report on November 9, 2026, disclosing plans to enter into non-redemption agreements with unaffiliated investors ahead of an extraordinary general meeting scheduled for November 17, 2026, to vote on extending the company's business combination deadline.
Immunovant, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $250.470 million for the six months ended September 30, 2026, with cash and cash equivalents of $722.274 million as of that date.
Cullinan Therapeutics, Inc. filed a current report on Form 8-K on November 9, 2026, disclosing interim clinical data from an ongoing Phase 1b/2a trial of velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus, as presented at the American College of Rheumatology Convergence …
Cadeler plc filed a Form 6-K with the U.S. Securities and Exchange Commission on 9 November 2026, announcing the initiation of a compulsory acquisition of shares in Cadeler A/S held by remaining minority shareholders under sections 70 and 72 of the Danish Companies Act.